Compare Flagstar Bank NA (FLG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs BIO-TECHNE Corp — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.69B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 2.4× Flagstar Bank NA's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and BIO-TECHNE Corp for 63 Days on average.
| FLG | TECH | |
|---|---|---|
Market Cap | $4.69B | $11.37B |
Volume | 6,174,553 | 3,153,511 |
Sector | Financials | Health |
52-Week High | $15.36 | $72.61 |
52-Week Low | $10.72 | $43.31 |
Typical Hold Time | 21 Days | 63 Days |
Enterprise Value | $15.23B | $11.40B |
Dividend Yield | 0.35% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.30, down 2.25% today, with a bearish technical signal despite bullish oscillators. The stock shows mixed fundamentals with a high P/E of 376.67 but trades below book value (P/B 0.61). Recent Q2 2026 earnings missed expectations, though the company reported its third consecutive profitable quarter. Analyst consensus remains strongly bullish with a $17.07 price target and no sell ratings.
The outlook suggests potential upside from current depressed levels, supported by analyst optimism and strategic initiatives like the $250M share repurchase program. Key risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. The stock presents a value opportunity but requires careful monitoring of execution on profitability targets.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
